Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R-Related Leukoencephalopathy

Recently, Tipton and coworkers\(^1\) reported on the results of allogeneic hematopoietic stem cell therapy (HSCT) in 7 individuals with CSF1R-related leukoencephalopathy. HSCT appeared to slow progression in most of them after about 6 months. An unresolved question is whether presymptomatic HSCT prevents the development of leukoencephalopathy in patients with pathogenic CSF1R variants or ameliorates the course if leukoencephalopathy subsequently develops.

We report the results of prophylactic HSCT in a 31-year-old woman who is heterozygous for the pathogenic CSF1R variant NM_002113.3(CSF1R):c.1754-2A>G previously detected in her family. She is the daughter of NO-2 in the report by Rademakers et al\(^2\) (Fig 1) and was clinically and radiologically unaffected at presentation. All affected relatives had rapidly devastating disease, resulting in death within 3 years of diagnosis.

Given the uniformly fatal outcome in her relatives, the woman requested HSCT, based on previous case reports.\(^3\) -5 HSCT was discussed at length with her and her family. The decision to provide treatment followed multiple rounds of discussion among neurologists, hematologists, and geneticists nationally, as well as consultation with expertise from France and the United States. HSCT was performed in August 2020, using the Mayo Clinic reduced intensity conditioning regimen\(^1\) with a 9/10 HLA-matched unrelated male donor bone marrow graft. Post-transplantation she received cyclophosphamide, sirolimus, and mycophenolate as graft versus host disease (GVHD) prophylaxis without pretreatment to open the blood–brain barrier. Engraftment was observed at day +20, and complete donor chimerism reached at day +27. Lumbar puncture at +12 months showed 99% donor chimerism in the cerebrospinal fluid; T-cells, B-cells, and monocytes were defined by morphology and flow cytometry. During the first 12 months post-transplantation, there were no manifestations of GVHD.

Clinical neurologic testing was unreproducible before HSCT and at +12 months. Cerebral magnetic resonance imaging (MRI) at –28, –11, –4, –3, and 0 months before HSCT was normal and remained so at +4, +8, and +12 months. Detailed neuropsychological testing performed at –5 months and repeated at +12 months was unreproducible.

One year after transplantation, the woman became subacutely ill. Her MRI was compatible with inflammation of the left temporal lobe, brainstem, medulla, and meninges. Mild pleocytosis was present in the cerebrospinal fluid, but no infectious agents were detected, and there was no evidence of malignancy or autoimmune disease despite extensive investigations. An allogeneic immunological reaction seems a probable but unproven cause. Clinically, she was mildly affected with subtle signs of myelopathy and modest cognitive difficulties. She improved spontaneously without medical intervention.

To our knowledge, this is the first report of allogeneic HSCT performed with the aim of preventing progressive, potentially fatal CSF1R-related leukoencephalopathy in an asymptomatic individual. At +17 months, evidence of leukoencephalopathy is absent. This is encouraging but is, of course, not proof of efficacy. The decision to provide HSCT was ethically challenging. We remain uncertain as to whether asymptomatic individuals with pathogenic CSF1R variants should be provided HSCT. Bridging therapies that could stem the progression of leukoencephalopathy,\(^6\) so that HSCT is delayed until MRI changes develop, might be a better option.

Acknowledgments: We thank Berit M. Dupuy and Marguerethe R. Stenersen, Department for Forensic Genetics, Oslo University Hospital, for chimerism analyses of cells from the cerebrospinal fluid.

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Morten Andreas Horn, MD, PhD,†* 3, 8
Anders Eivind Myhre, MD, PhD, 2 Trine Prescott, MD, 3
Jan Asay, MD, PhD, 4, 5
Christina Heidemann Sundal, MD, PhD, 6, 7 and
Tobias Gedde-Dahl, MD, PhD 2, 8
1Department of Neurology, Oslo University Hospital, Oslo, Norway,
2Department of Hematology, Oslo University Hospital, Oslo, Norway,
3Section of Medical Genetics, Department of Laboratory Medicine, Telemark Hospital Trust, Skien, Norway,
4Department of Neurology, St. Olavs Hospital, Trondheim, Norway,
5Department of Neuroscience, NTNU, Trondheim, Norway,
6Department of Neurology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, and
7Division of Medicine, Institute for Clinical Medicine, University of Oslo, Oslo, Norway

References

1. Tipton PW, Kenney-Jung D, Rush BK, et al. Treatment of CSF1R-related leukoencephalopathy: breaking new ground. Mov Disord 2021;36:2901–2909.

2. Rademakers R, Baker M, Nicholson AM, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet 2011;44:200–205.

3. Echler FS, Li J, Guo Y, et al. CSF1R mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroids. Brain 2016;139:1666–1672.

4. Mochel F, Delorme C, Czernecki V, et al. Haematopoietic stem cell transplantation in CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. J Neurol Neurosurg Psychiatry 2019;90:1375–1376.

5. Gelfand JM, Greenfield AL, Barkovich M, et al. Allogeneic HSCT for adult-onset leukoencephalopathy with spheroids and pigmented glia. Brain 2020;143:503–511.

6. Tipton PW, Stanley ER, Chitu V, Wszolek ZK. Is pre-symptomatic immunosuppression protective in CSF1R-related leukoencephalopathy? Mov Disord 2021;26:852–856.

Reply to “Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R-Related Leukoencephalopathy”

We congratulate Horn and colleagues on being the first to successfully administer hematopoietic stem cell transplantation (HSCT) to an asymptomatic carrier of a pathogenic CSF1R variant. 1

Our recent paper 2 adds to the growing body of literature supporting HSCT as a disease-modifying therapy with the ability to stabilize and even improve the neurological function of patients with CSF1R-related leukoencephalopathy (CSF1RL). Although this is an exciting advancement in the field, heterogeneity of clinical outcomes with HSCT demonstrates that we currently do not know which patients are the best candidates for HSCT. Based on our work and the work of others, we present a hypothetical model for CSF1RL progression and propose the optimal treatment window for HSCT (Fig. 1).

Current literature best informs when the treatment window for HSCT in CSF1RL has closed. Within our series, patient 2 was one of the most severely affected individuals (clinical symptoms and magnetic resonance imaging changes) 3 during transplant. Follow-up at 20 months demonstrated a continued, albeit slowed, rate of clinical and radiographic progression. We suspect that HSCT earlier in the disease course portends a better prognosis as illustrated by our patient 4. 2 Thus, patients will likely have the best clinical outcomes if HSCT is administered while they are in the prodromal to early-moderate stages of symptomatic disease (Fig. 1).

Horn and colleagues were presented with a unique, likely to recur, decision-making process on how early HSCT can be performed. Given the rapidly progressive nature of CSF1RL, early symptomatic or even presymptomatic treatment is expected to provide the greatest benefit. We suggest that a carrier of a pathogenic CSF1R variant who is experiencing first signs of symptomatic disease, clinically, radiologically, or both, is probably the best candidate for HSCT. Asymptomatic CSF1R variant carriers are usually identified because of their family relationship to a person with symptomatic CSF1RL. These individuals should be followed closely to identify the earliest evidence of symptom onset. As demonstrated by the case of Horn et al. 1 we presently do not recommend prophylactic HSCT for asymptomatic carriers because CSF1R pathogenic variants have high but incomplete penetrance. 4

CSF1RL is associated with reduced blood–brain barrier (BBB) permeability 5; however, it is unclear how much disease progression is necessary for transplanted microglial precursor cells to efficiently traverse the BBB. HSCT pretreatment to increase BBB permeability can be administered; however, the case presented by Horn and colleagues achieved more than 99% donor chimerism in cerebrospinal fluid (CSF) without pretreatment. This suggests sufficient BBB permeability, presumably from the emerging leukoencephalopathy, despite the absence of clinical or radiographic disease manifestations, that is, presymptomatic. Nevertheless, confidence that CSF1R variant carriers are truly “presymptomatic” is based only on penetrance probabilities, and there is a need for reliable disease biomarkers. A recent study found elevated serum and CSF neurofilament light (NFL) chain in asymptomatic CSF1R mutation carriers. 6 NFL levels could equip clinicians for determining whether an asymptomatic carrier is “presymptomatic” if appropriate cutoff values are determined. Then, it would be reasonable to discuss prophylactic HSCT with presymptomatic CSF1R pathogenic variant carriers.

© 2022 International Parkinson and Movement Disorder Society

Key Words: CSF1R-related leukoencephalopathy; stem cell transplantation; genetics; treatment

*Correspondence to: Dr. Zbigniew K. Wszolek, Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA; E-mail: wszolek.zbigniew@mayo.edu

LETTERS: PUBLISHED ARTICLES

Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.29018